STAT3 inhibitor Stattic and its analogues inhibit STAT3 phosphorylation and modulate cytokine secretion in senescent tumour cells

0571758 - ÚMG 2024 RIV GR eng J - Journal Article
Mikyšková, Romana - Sapega, Olena - Psotka, M. - Novotný, Ondřej - Hodný, Zdeněk - Bálintová, Soňa - Malinak, D. - Svobodová, J. - Andrýs, R. - Ryšánek, David - Musílek, K. - Reiniš, Milan
STAT3 inhibitor Stattic and its analogues inhibit STAT3 phosphorylation and modulate cytokine secretion in senescent tumour cells.
Molecular Medicine Reports. Roč. 27, č. 4 (2023), č. článku 81. ISSN 1791-2997. E-ISSN 1791-3004
R&D Projects: GA MŠMT LX22NPO5102; GA MZd NV18-05-00562
Institutional support: RVO:68378050
Keywords : cellular senescence * docetaxel * signal transducer and activator of transcription 3 inhibition * Stattic * senescence-associated secretory phenotype
OECD category: Immunology
Impact factor: 3.4, year: 2022
Method of publishing: Open access
https://www.spandidos-publications.com/10.3892/mmr.2023.12968

Signal transducer and activator of transcription 3 (STAT3) signalling serves an important role in carcinogenesis and cellular senescence, and its inhibition in tumour cells represents an attractive therapeutic target. Premature cellular senescence, a process of permanent proliferative arrest of cells in response to various inducers, such as cytostatic drugs or ionizing radiation, is accompanied by morphological and secretory changes, and by altered susceptibility to chemotherapeutic agents, which can thereby complicate their eradication by cancer therapies. In the present study, the responsiveness of proliferating and docetaxel (DTX)-induced senescent cancer cells to small molecule STAT3 inhibitor Stattic and its analogues was evaluated using tumour cell lines. These agents displayed cytotoxic effects in cell viability assays on both proliferating and senescent murine TRAMP-C2 and TC-1 cells, however, senescent cells were markedly more resistant. Western blot analysis revealed that Stattic and its analogues effectively inhibited constitutive STAT3 phosphorylation in both proliferating and senescent cells. Furthermore, whether the Stattic-derived inhibitor K1836 could affect senescence induction or modulate the phenotype of senescent cells was evaluated. K1836 treatment demonstrated no effect on senescence induction by DTX. However, the K1836 compound significantly modulated secretion of certain cytokines (interleukin-6, growth-regulated oncogene alpha and monocyte chemoattractant protein-1). In summary, the present study demonstrated differences between proliferating and senescent tumour cells in terms of their susceptibility to STAT3 inhibitors and demonstrated the ability of the new STAT3 inhibitor K1836 to affect the secretion of essential components of the senescence-associated secretory phenotype. The present study may be useful for further development of STAT3 inhibitor-based therapy of cancer or age-related diseases.
Permanent Link: https://hdl.handle.net/11104/0343048